Fig. 1

Expression of Transgelin-2 (TAGLN2) in the biliary tract cancer cell (BTC)-spheres. (A) Sphere-formation assays of BTC cell lines, including SNU245, SNU308, SNU869, and SNU1196. The cells were maintained in growth media and plated onto culture dishes or ultra-low attached plates in sphere media. (B) Differentially expressed genes and (C) proteins analyzed in sphere-cultured cells in SNU245 and SNU1196. (D) Tumorigenesis was performed using adherent and sphere-cultured SNU1196 in vivo. (E) Differentially expressed genes were analyzed using microarray analysis; 65 genes were overexpressed in both sphere cultured SNU245 and SNU1196 cells (Fold change, FC > 1.2) as well as in biliary tract cancer patient tissues (FC > 2); TAGLN2 was selected from the microarray analysis. (F)TAGLN2 expression in all BTC cell lines analyzed using PCR. In B, C, D, and F: Adh, adherent cells; Sph, sphere cells